Clinical Trial Update: The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib [Phase 4]

View source ↗

Summary

A Phase 4 study assessing how esomeprazole, a proton pump inhibitor, affects the bioavailability of regorafenib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Gastrointestinal Stromal Tumors

Drugs mentioned

• Esomeprazole (Esomeprazole)
• Regorafenib (regorafenib)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Colorectal Neoplasms, Gastrointestinal Stromal Tumors | Phase 4 | Status: COMPLETED